aavcagscd59
Gene therapyexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 29, 2017 (NCT03144999)
Timeline
Indications
Mechanism of action
- Unspecified targetANTAGONIST
antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aavcagscd59
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06635148 | Phase 2 | Sep 19, 2024 | — |
| NCT05811351 | Phase 2 | Mar 6, 2023 | — |
| NCT04358471 | Phase 2 | Jun 30, 2020 | Hemera Biosciences |
| NCT03585556 | Phase 1 | Sep 13, 2018 | Hemera Biosciences |
| NCT03144999 | Phase 1 | Mar 29, 2017 | Hemera Biosciences, Ophthalmic Consultants of Boston |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hemera Biosciences | For profit | 3 | 3 | 2 | 2017 |
| Ophthalmic Consultants of Boston | Academic/Hospital | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1